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activity. Importantly, inhibition of NFkB with Bay 11-7085 (8.5 
mM) leads to loss of cell viability and is accompanied by decreased 
levels of HSP70 and HSP27, as well as their transcription factor, 
HSF-1, at the RNA and protein levels. Furthermore, overexpression 
of a phosphorylation-deficient mutant of IKBa in MIAPaCa-2 cells 
resulted in decreased NFkB activity and the loss of HSP70 expression.
Conclusion: HSP70 is known to be regulated by several mechanisms. 
Here we show a novel NFkB-mediated mechanism by which HSF-1 
and its transcriptional targets, HSP27 and HSP70 are down-regulated 
in pancreatic cancer cells in response to triptolide.
Disclosure of Interest: U. Matsathit: None declared. O. McGinn: 
None declared. V. Sangwan: None declared. S. Banerjee: None 
declared. L. Phivthong-ngam: None declared. A. Saluja: Other: Chief 
Scientific Officer, Minneamrita Therapeutics.
PP116—Metastatic breast carcinoMa 
induces vascular endothelial 
dysfunction in balb-c Mice: role of 
tuMor necrosis factor-α lPha and nadPh-
oxidase
S. Dalaklioglu1*; A. Tasatargil1; S. Kale1; G. Tanriover2;  
S. Dilmac2; and N. Erin1
1Department of Pharmacology; and 2Department of Histology and 
Embryology, Akdeniz University Medical Faculty, Antalya, Turkey
Introduction: Although the oxidative stress and inflammation are 
closely related with breast cancer, there is no study directly examining 
the possible changes in vascular functions in the presence of breast 
carcinoma. The goal of the present study was to evaluate changes in 
vascular reactivity in tumor-bearing mice.
Patients (or Materials) and Methods: In this study, highly metastatic 
breast carcinoma cells which was derived from liver or brain metasta-
sis of 4T1 murine breast carcinoma (4TLM and 4TBM, respectively), 
and 67NR cells which is tumorogenic but nonmetastatic cells were 
used. Female Balb-c mice 8 to 10 weeks old were divided into fol-
lowing groups: (1) control; (2) injected with 67NR; (3) injected with 
4TLM; and (4) injected with 4TBM orthotopically. Thoracic aorta 
was removed 25 days after injection of tumor cells. Isometric tension 
studies were performed in response to potassium chloride (KCl), 
phenylephrine (Phe), acetylcholine (ACh, an endothelium-depend-
ent vasodilator), and sodium nitroprusside (SNP, an endothelium-
independent vasodilator). Endothelial nitric oxide synthase (eNOS), 
phosphorylated eNOS (Ser 1177) (p-eNOS), gp91phox, and tumor 
necrosis factor-α (TNF-α ) expressions in aortic tissues were demon-
strated by immunohistochemistry. The level of TNF-α in vascular 
tissue was evaluated by ELISA.
Results: Presence of tumor was resulted in significant inhibition of 
response to ACh in both 4TLM- and 4TBM-injected mice but not 
67NR-injected mice. Furthermore, both KCl and Phe-induced con-
traction of thoracic aorta was not changed significantly in tumor-
bearing animals. eNOS and p-eNOS expressions decreased while 
gp91phox and TNF-α expressions increased in endothelium sig-
nificantly in mice with metastatic breast carcinoma compared with 
67NR-injected and control mice. Moreover, TNF-α levels of thoracic 
aorta in 4TLM and 4TBM mice were higher than that of 67NR mice. 
Tumor-induced endothelial dysfunction determined by ACh-induced 
relaxation improved by superoxide dismutase (SOD), apocynin (a 
NADPH oxidase inhibitor), and infliximab (a TNF-α monoclonal 
antibody).
Conclusion: The findings of this study suggest that presence of 
metastatic breast carcinoma may cause a significant reduction in 
endothelium-dependent relaxation of thoracic aorta via NADPH 
oxidase-mediated oxidative stress and TNF-α production.
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Introduction: Cyclin D1 is required for cells to progress from the 
G1 phase of the cell cycle into the S phase. Mutation or overexpres-
sion of cyclin D1, often occurring in tumors, leads to uncontrolled 
cell cycle progression and proliferation. QTRRE (rodent) as well 
as ACHN and 786-O (human) cell models of renal cell carcinoma 
(RCC) display elevated cyclin D1 protein levels. Pentoxifylline (PTX), 
an FDA-approved competitive, nonspecific phosphodiesterase inhibi-
tor, has found recent use as an adjunct in chemotherapy for patients 
to help treat cachexia and capillary leak syndrome.
Patients (or Materials) and Methods: We utilized Western blot analy-
sis as well as propidium iodide-based cell cycle analysis to study the 
effects of PTX in our RCC cell models.
Results: Initially (0–8 hours), PTX induced a time- and dose- 
(35 µM–3.5 mM) dependent decrease in cyclin D1 levels in the RCC 
cell models. Cotreatment with PTX and the protein translation 
inhibitor, cycloheximide (5–25 µM), revealed a decrease in cyclin 
D1 protein half-life. Furthermore, the PTX-induced decrease of cyclin 
D1 was abolished in the presence of a proteasome inhibitor (MG-
132, 10 µM) in all 3 RCC cell models. Subsequently (12–72 hours), 
PTX caused maximal cyclin D1 decreases in QTRRE and ACHN 
cells, whereas cyclin D1 levels in 786-O cells recovered and surpassed 
initial amounts seen in the control. Concomitant with cyclin D1 lev-
els, QTRRE and ACHN cells demonstrated enhanced G1 phase cell 
cycle arrest at 24 hours (170% and 140%, respectively) compared 
with 786-O cells (107%) and the nontumorigenic human kidney cell 
line HK-2 (107%).
Conclusion: The data suggest that PTX decreases cyclin D1 protein 
levels by stimulating proteasomal degradation (and subsequent G1 
phase arrest), which is sustained in the QTRRE and ACHN but not 
786-O RCC cell models. The data reveal a need to better under-
stand the differences in PTX response between the RCC cell models. 
Moreover, an ability to predict a positive response to PTX may con-
tribute to better personalized cancer therapy treatment for patients. 
Because our findings also reveal a novel anticancer chemotherapeutic 
property of PTX, the utility of PTX as an adjuvant therapy in the 
treatment of cancer should be further explored.
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Introduction: Photodynamic therapy (PDT) is an anticancer treat-
ment that uses light to activate cytotoxic compounds killing cancer 
cells. Sonodynamic therapy (SDT) is a new anticancer treatment 
where ultrasound is used to trigger the cytotoxic effect of chemical 
compounds known as sonosensitizers. SDT is able to focus the ultra-
sound energy, generated by selected continuous or pulsed ultrasound 
such as shock waves (SW), onto malignant sites situated deeply inside 
tissues overcoming the main drawback linked to the use of PDT: the 
poor penetration of light in biological tissues. Even if the SDT mecha-
nism is still under debate, some researchers suggest a common basic 
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principle for PDT and SDT. Therefore, in vitro comparison of PDT 
and SDT effects can provide insight into SDT mechanism of action. 
We have investigated PDT and SDT effects on human melanoma 
and fibrosarcoma cell lines, previously exposed to 5 aminolevulinic 
acid (Ala), through cell proliferation, cell death, and gene expression 
analysis.
Patients (or Materials) and Methods: The human melanoma, A2058, 
and fibrosarcoma, HT-1080, cell lines were previously exposed to Ala 
(0.45 mM) for 12 and 4 hours, respectively. SW generated by a piezo-
electric device (Piezoson 100, Wolf) were used for SDT. In particular, 
A2058 were treated with an energy flux density (EFD) of 0.32 mJ/
mm2 for 1000 shots (4 shots/sec) while HT-1080 were treated with 
an EFD of 0.43 mJ/mm2 for 500 shots (4 shots/sec). A LED lamp at 
405 nm was used for PDT and both cell lines were treated for 5 min 
at 15 mW. Cell growth was evaluated by WST-1 assay, cell death by 
flow cytometric analysis with SYTOX Green and APC-Annexin V 
and mRNA expression by real-time RT-PCR.
Results: In A2058 both treatments determined a significant cell 
growth reduction even if SDT produced a progressive cell growth 
decrease compared with PDT reaching the greatest decrease at 72 
hours (P < 0.01). Moreover, cell death evaluation highlighted a 25% 
increase of apoptotic cells at 48 hours from SDT. Both PDT and 
SDT determined a significant overexpression of the pro-apoptotic 
gene BAX and of the genes involved in the oxidative stress, NQO1 
and SOD2. In HT-1080, SDT was more effective than PDT with a 
more significant increase of apoptotic cells compared with PDT (P < 
0.01).After both treatments a significant overexpression of the pro-
apoptotic gene APAF1 was observed.
Conclusion: After PDT and SDT a similar gene expression profile 
was observed in both cell lines, even though SDT seems more effective 
on fibrosarcoma cells and PDT on melanoma cells.
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Introduction: Curcumin possesses anticancer, anti-inflammatory, 
antioxidant, and antimicrobial properties. Curcumin has a poor oral 
bioavailability and solubility in plasma. Accordingly, various drug 
delivery systems, such as liposomal preparation, have been developed 
for intravenous administration. However, animal studies have shown 
dose-dependent hemolysis after infusion of liposomal curcumin. 
Because blood cells are the first point of contact for liposomal cur-
cumin when administered intravenously, we investigated the influence 
of curcumin on human red blood cell (RBC) morphology in vitro.
Patients (or Materials) and Methods: Whole blood buffered with 
EDTA was incubated with different concentrations (1, 10, 100 μ g/
mL) of free or liposomal formulations of curcumin. RBC morphology 
and mean cellular volume were examined after 30 minutes, 1 hour, 2 
hours, and 4 hours of incubation.
Results: Dose-dependent echinocyte formation was observed after 
incubation with free and liposomal Curcumin, with a threshold con-
centration of 10 µg/mL and peak effect after 30 minutes of incuba-
tion. Treatment with empty liposomes also resulted in RBC shape 
change. A concomitant increase in mean red blood cell volume was 
detectable.
Conclusion: Curcumin, liposomes and liposomal curcumin dose-
dependently change RBC morphology. This effect is additive and may 
represent a first sign of toxicity following intravenous administration.
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Introduction: In search for drugs that can target cancer cell microen-
vironment in as much as being able to halt malignant cellular trans-
formation, the natural dietary phytochemical curcumin was currently 
assessed in DMH-induced colorectal cancer rat model.
Patients (or Materials) and Methods: The study enrolled 50 animals 
divided into a control group (n = 10) and DMH-induced colorectal 
cancer control group (n = 20) (20 mg/kg.-body weight for 28 weeks) 
versus curcumin-treated group (n = 20) (160 mg/kg suspension daily 
oral for further 8 weeks).
Experimental Procedures: ACF Assay: The colonic lesion biopsies 
were stained by 30% methylene blue for light microscopic examina-
tion [using a 40 magnification to transluminate the specimens] in 
search for lesions fulfilling Mc Lellan and Bird criteria
Histopathological Examination: By using light microscopic 
assessment.
Biochemical Estimations in Colonic Tissues: Malondialdehyde 
(MDA) Assay, reduced glutathione (GSH) Assay, Cyclooygenase-2 
(COX-2) activity measurement, tumor necrosis factor-α (TNF-α 1 
Determination, platelet activating factor (PAF) activity measurement, 
transformaing growth factor-β (TGF-β ) determination:
Results: Treatment by curcumin succeeded to significantly decrease 
the percent of ACF and tended to normalize back the histologic 
changes retrieved in adenomatous and stromal cells induced by 
DMH. The drug also significantly elevated GSH and significantly 
reduced most of the accompanying biochemical elevations (namely 
MDA, TNF-α , TGF-β , and COX2) observed in colonic carcinoma-
tous tissue, induced by DMH, thus succeeding to revert that of MDA, 
COX2& TGF-β back to near normal as justified by being nonsignifi-
cantly altered compared with normal controls. The only exception 
was PAF, which was insignificantly altered by the drug.
Conclusion: When taken together, it could be concluded that cur-
cumin possess the potentiality to halt some of the orchestrated cross-
talk between cancerous transformation and its microenvironmental 
niche that contributes to cancer initiation, progression, and metasta-
sis in this experimental cancer colon model. Envisioning these merits 
to a drug with an already known safety preferentiality, awaits final 
results of current ongoing clinical trials, before curcumin can be 
added to the new therapeutic armamentarium of anticancer therapy.
Disclosure of Interest: None declared.
PP121—cyP2c9 genotyPes associated with 
higher sulfolane levels in children 
receiving intravenous busulfan Prior to 
heMatoPoietic steM cell transPlantation
C.R.S. Uppugunduri1,2*; Y. Daali3; M.A. Rezgui4; P. Huezo Diaz1,2; 
A.K. Tyagi1,2; J. Rousseau4; M. Duval4,5; H. Bittencourt4,5;  
M. Krajinovic4,6,7; and M. Ansari1,2
1Department of Pediatrics, Hemato-oncology unit, University of 
Geneva; 2CANSEARCH research laboratory, Geneva Medical 
